Clinical Trial Update: A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating alemtuzumab (Campath) in patients with myelodysplastic syndromes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2018-09-24